Introduction
Acute oxalate nephropathy (1-3) may be an under-reported, yet important complication of malabsorption-inducing weight loss supplements (4, 5) . We report on a patient taking orlistat, a lipase inhibitor, who presented with acute kidney injury (AKI) due to oxalate deposition.
Case Presentation
Our patient was a 76-year-old white female with a past medical history of chronic kidney disease (CKD), baseline creatinine 1.85 mg/dL (estimated glomerular filtration rate 27 ml/min/1.73 m 2 ; creatinine range 1.5-2.5 mg/dL six months prior to admission), hypertension, gout and psoriatic arthritis, who was admitted to the hospital for evaluation of elevated 
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Background: Obesity is a major world-wide epidemic which has led to a surge of various weight loss-inducing medical or surgical treatments. Orlistat is a gastrointestinal lipase inhibitor used as an adjunct treatment of obesity and type 2 diabetes mellitus to induce clinically significant weight loss via fat malabsorption. Case Presentation: We describe a case of a 76-year-old female with past medical history of chronic kidney disease (baseline serum creatinine was 1.5-2.5 mg/dL), hypertension, gout and psoriatic arthritis, who was admitted for evaluation of elevated creatinine, peaking at 5.40 mg/dL. She was started on orlistat 120 mg three times a day six weeks earlier.
Initial serologic work-up remained unremarkable. Percutaneous kidney biopsy revealed massive calcium oxalate crystal depositions with acute tubular necrosis and interstitial inflammation. Serum oxalate level returned elevated at 45 mm/l (normal <27). Timed 24-hour urine collection documented increased oxalate excretion repeatedly (54-96 mg/24 hour). After five renal dialysis sessions in eighth days she gradually regained her former baseline kidney function with creatinine around 2 mg/dL. Given coexisting proton-pump inhibitor therapy, only per os calcium-citrate provided effective intestinal oxalate chelation to control hyperoxaluria. Conclusions: Our case underscores the potential of medically induced fat malabsorption to lead to an excessive oxalate absorption and acute kidney injury (AKI), especially in subjects with pre-existing renal impairment. Further, it emphasizes the importance of kidney biopsy to facilitate early diagnosis and treatment. (Table 1) . Urine oxalate excretion came under acceptable control with per os calciumcitrate dosed at 2080 mg, to be taken three times a day with meals (Table 1) .
Discussion
Obesity is a major world-wide epidemic linked to a number of chronic health risks such as heart disease, diabetes and high blood pressure (9,10). It has been reported to affect about one-third of the American adult population (9) and a recognized risk factor for kidney disease (10) . Orlistat is a gastrointestinal lipase inhibitor used as an adjunct treatment of obesity and type 2 diabetes mellitus, to induce clinically significant weight loss by causing fat malabsorption. Malabsorption of intestinal lipids would, however, lead to increased "saponification" of calcium in the gastrointestinal tract and decreases calcium availability to form insoluble calcium oxalate complexes. The decreased binding of oxalate will lead to excessive oxalate absorption and will also appear in the urine. Due to the low solubility of oxalate, increased concentrations of oxalate in the body can lead deposition of calcium oxalate in the kidney tissue resulting in nephrocalcinosis, nephrolithiasis, and ultimately progressive renal insufficiency1. Both anti-obesity (bariatric) surgery (11) and orlistat administration is known to increase urinary appearance of oxalate (12) . Acute oxalate nephropathy (AON) is defined as renal insufficiency in the presence of calcium oxalate crystal deposition in the renal interstitium and renal tubular cells (4, 5) . Currently, there is very limited data reported regarding orlistatinduced AON in the United States. The first case reported in 2007 described a patient with AON with a temporal relationship to an increased dose of orlistat and the development of increased fat malabsorption (more frequent loose oily stools) (4). Additional case reports have been described since (5, 13, 14) . More comprehensively, a Canadian study of 953 patients reviewed the incidence of AKI twelve months before and after starting orlistat (15) . The incidence of AKI twelve months before was 5 cases and 18 cases after. Our case, similar to past reported experience (16) , also documented co-existing acute tubular necrosis (ATN) along with the crystal deposition. ATN is a common finding on renal biopsies when an acute rise of creatinine is documented in sick inpatients (17, 18) . Oxalate depositions are very common in kidney biopsies immediately after renal transplant and dialysis patients are known to have markedly elevated serum and tissue oxalate content (19, 20) . In our case, early initiation of temporary renal replacement therapy may have contributed to the excellent functional recovery. Other potential cause of oxalate deposition in this case was the intake of vitamin-C, which not an uncommon in complementary and alternative medicine and is also known precursor of oxalate (21, 22) . However, she has been taking her vitamin-C supplements already for years at the same dose unchanged. Ethylene glycol exposure may result in similar presentation (23), but she had no history of antifreeze exposure and serum anion gap was not elevated on admission. Unlike some of past cases (13), our patient did have a persistently elevated urinary oxalate excretion, even after cessation of orlistat therapy. It is uncertain, whether some or all of the reported individuals in the reported literature to date had an underlying mild or partial enzyme deficiency of alanine: glyoxylate aminotransferase, further aggravated by orlistat administration. Further, it is unclear, whether calcium supplement, originally intended as phosphorus binders do also reduce oxalate absorption and serum oxalate levels to a meaningful degree in advanced (stage 4-5) CKD patients. AON may be an under-recognized and important cause of renal failure in patients taking fat malabsorption-inducing weight loss supplements through hyperoxaluria.
Conclusions
Acute oxalate nephropathy is an important entity to recognize in patients taking weight loss supplements. 
